Literature DB >> 21916740

Examining reports and policies on cognitive enhancement: approaches, rationale, and recommendations.

Simon M Outram1, Eric Racine.   

Abstract

The phenomenon of cognitive enhancement is attracting attention in bioethics literature and beyond, in public policy. In response, three bodies--the British Medical Association (BMA); the Commission de l'éthique de la Science et de la technologie (CEST) du Québec; the American Academy of Neurology (AAN)--have produced reports and guidance on this topic. To gain insights into different public policy approaches, rationales, and recommendations on the topic, we analyzed these reports in depth. We found convergence on the definition (with the exception of the CEST) of cognitive enhancement. However, we noted a lack of critical reflection with respect to the underlying rationale for developing these reports, i.e., that cognitive enhancement practices are rampant and represent major social changes. As it currently stands, cognitive enhancement is constituted in a way that challenges the creation of coherent and effective policy recommendations. However, policy makers should not simply wait for definitional consensus and hope that on balance the benefits turn out to be greater than the risks. Some components of cognitive enhancement could be reduced down to clearly identified policy targets to be further examined. Then, if appropriate, policy should be created that is, amongst other criteria, beneficial to the majority of the population.

Mesh:

Substances:

Year:  2011        PMID: 21916740     DOI: 10.1080/08989621.2011.606734

Source DB:  PubMed          Journal:  Account Res        ISSN: 0898-9621            Impact factor:   2.622


  2 in total

1.  The value and pitfalls of speculation about science and technology in bioethics: the case of cognitive enhancement.

Authors:  Eric Racine; Tristana Martin Rubio; Jennifer Chandler; Cynthia Forlini; Jayne Lucke
Journal:  Med Health Care Philos       Date:  2014-08

2.  Generating genius: how an Alzheimer's drug became considered a 'cognitive enhancer' for healthy individuals.

Authors:  Lucie Wade; Cynthia Forlini; Eric Racine
Journal:  BMC Med Ethics       Date:  2014-05-12       Impact factor: 2.652

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.